Medical News / AAO 2021: Optogenetics Product Provides Safe Treatment Opportunity for Retinitis Pigmentosa Reversal

An optogenetics device in combination with gene therapy is proving safe, tolerable and, according to case series reports, efficacious in the treatment of end-stage blindness in patients with retinitis pigmentosa (RP). In a presentation at the American Academy of Ophthalmology (AAO) 2021 Meeting in New Orleans this week, Jose A. Sahel, MD, Chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine and Director of the UPMC Eye Center, provided an update on GenSight Biologics’ product candidate GS030, an external wearable medicine device promised of biomimetic googles that provide a light source in patients with RP. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more